false
--12-31
0001479419
0001479419
2026-11-12
2026-11-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 12, 2026
KALA BIO, Inc.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-38150 |
|
27-0604595 |
(State
or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
1167 Massachusetts Avenue
Arlington, MA |
|
02476 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (781) 996-5252
(Former name or former address,
if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol |
|
Name of each exchange on which registered |
| Common
Stock, par value $0.001 per share |
|
KALA |
|
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 3.03. | Material Modification to Rights of Security Holders. |
To the extent required by Item 3.03 of Form 8-K,
the information contained in Item 5.03 of this report is incorporated herein by reference.
| Item 5.03. | Amendments to Articles of Incorporation or Bylaws; Change
in Fiscal Year. |
On November 12, 2026, KALA BIO, Inc. (the “Company”)
filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Restated Certificate
of Incorporation (as amended, the “Certificate of Incorporation”) with the Secretary of State of Delaware to
effect a 1-for-30 reverse stock split of the shares of the Company’s common stock, par value $0.001 per share (the “Common
Stock”), either issued and outstanding or held by the Company as treasury stock, effective as of 4:05 p.m. (Delaware time)
on November 13, 2026 (the “Reverse Stock Split”). As previously reported, the Company held its 2026 annual meeting
of stockholders on November 3, 2026 (the “Annual Meeting”), at which Annual Meeting the Company’s stockholders
approved the Certificate of Amendment to effect a reverse stock split of the Company’s Common Stock at a ratio in the range of 1-for-2
to 1-for-300, with such ratio to be determined by the Company’s Board of Directors (the “Board”) and included
in a public announcement. The Board determined to effect the Reverse Stock Split at a ratio of 1-for-30 and approved the corresponding
final form of the Certificate of Amendment.
As a result of the Reverse Stock Split, every
thirty (30) shares of issued and outstanding Common Stock will be automatically combined into one (1) issued and outstanding share of
Common Stock, without any change in the par value per share. No fractional shares will be issued as a result of the Reverse Stock Split.
Stockholders that would hold fractional shares as a result of the Reverse Stock Split are entitled to receive a cash payment in lieu of
said fractional shares based on the closing price on the Nasdaq Capital Market on November 12, 2026. The Reverse Stock Split will reduce
the number of shares of Common Stock outstanding from 19,339,786 shares to approximately 644,659 shares, subject to adjustment for the
rounding up of fractional shares. The number of authorized shares of Common Stock under the Certificate of Incorporation will remain unchanged
at 1,500,000,000 shares.
Proportionate adjustments will be made to the
per share exercise price and the number of shares of Common Stock that may be purchased upon the exercise or conversion, as applicable,
of outstanding equity awards under the Company’s 2009 Employee, Director and Consultant Equity Incentive Plan, Amended and Restated
2017 Equity Incentive Plan (the “2017 Equity Plan”) and the and Amended and Restated 2017 Employee Stock Purchase Plan (the
“2017 Stock Plan”). The number of shares reserved for issuance under the 2017 Equity Plan and 2017 Stock Plan will be proportionately
reduced in accordance with the terms of such plans.
The Common Stock will begin trading on a Reverse
Stock Split-adjusted basis on the Nasdaq Capital Market on November 16, 2026. The trading symbol for the Common Stock will remain “KALA.”
The new CUSIP number for the Common Stock following the Reverse Stock Split is 483119400.
For more information about the Reverse Stock Split,
see the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission September 24, 2026, the relevant
portions of which are incorporated herein by reference. The information set forth herein is qualified in its entirety by reference to
the complete text of the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated
herein by reference.
On November 12, 2026, the Company issued a press
release announcing the Reverse Stock Split. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form
8-K and incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
| Exhibit
No. |
|
Description |
| 3.1 |
|
Certificate of Amendment to the Restated Certificate of Incorporation, as amended, of KALA BIO, Inc. |
| 99.1 |
|
Press Release, issued on November 12, 2026. |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| |
KALA BIO, INC. |
| |
|
|
| Date: November 12,
2026 |
By: |
/s/ Avi Minkowitz |
| |
Name: |
Avi Minkowitz |
| |
Title: |
Chief
Executive Officer |
Exhibit 99.1
KALA BIO Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on November 16, 2026
Arlington, MA, November 12, 2026 (GLOBE NEWSWIRE) — KALA BIO, Inc. (NASDAQ: KALA) (“KALA BIO” or the “Company”), today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ratio of 1 post-split share for every 30 pre-split shares. The reverse stock split will become effective at 4:05 p.m. on Friday, November 13, 2026. The Company’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol KALA and will begin trading on a split-adjusted basis when the market opens on Monday, November 16, 2026. The new CUSIP number for the common stock following the reverse stock split is 483119400.
At a special meeting of stockholders, held on November 3, 2026, the Company’s stockholders granted the Company’s Board of Directors the discretion to effect a reverse stock split of the Company’s common stock through an amendment to its Restated Certificate of Incorporation, as amended, at a ratio of not less than 1-for-2 and not more than 1-for-300, with such ratio to be determined by the Company’s Board of Directors.
At the effective time of the reverse stock split, every thirty (30) shares of the Company’s issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share. Stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 1-for-30 reverse stock split. It is not necessary for stockholders holding shares of the Company’s common stock in certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish.
The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. No fractional shares will be issued. Stockholders that would hold fractional shares as a result of the Reverse Stock Split are entitled to receive a cash payment in lieu of said fractional shares based on the closing price on the Nasdaq Capital Market on November 12, 2026. The reverse stock split will reduce the number of shares of the Company’s common stock outstanding from 19,339,786 shares to approximately 644,659 shares. Proportional adjustments will be made to the number of shares of the Company’s common stock issuable upon exercise or conversion of the Company’s equity awards, warrants and other convertible securities, as well as the applicable exercise or conversion price thereof. Stockholders with shares in brokerage accounts should direct any questions concerning the reverse stock split to their broker; all other stockholders may direct questions to the Company’s transfer agent, Equiniti Trust Company, LLC, at (929) 469-2386.
ABOUT KALA BIO (NASDAQ: KALA)
KALA BIO, Inc. is a clinical-stage
biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The Company’s
dual strategy combines a proprietary biologics pipeline—including its mesenchymal stem cell secretome (MSC-S) platform and FDA
Orphan Drug- and Fast Track-designated product candidates—with a scalable AI platform-as-a-service business that deploys secure,
purpose-built AI solutions directly within biotech and pharmaceutical client environments.Through its exclusive worldwide license for
the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology
industry, enabling organizations of all sizes to unlock the value of their proprietary biological data without surrendering control.
Kala is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable
scalable, governed deployment of AI agents across research, documentation, and operational workflows. The Company’s focus on enterprise
security, real-time performance, and seamless integration positions it at the forefront of innovation in the life sciences AI sector.
Kala believes the future of biomedical innovation is in agentic systems.
For more information, visit
www.kalarx.com and www.Researgency.ai
Forward-looking Statements
This press release contains
“forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements
may be preceded by the words “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,” “would”
and similar expressions. Forward-looking statements are not guarantees of future performance, are based on certain assumptions
and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot
be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with: the effect that the reverse
stock split may have on the price of the Company’s common stock; the Company’s ability to maintain its listing on the Nasdaq
Capital Market; and other risks detailed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K as they
may be revised in the Company’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and other filings with the Securities
and Exchange Commission. More detailed information about the Company and the risk factors that may affect the realization of forward-looking
statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s web site at: http://www.sec.gov. The Company assumes no obligation to publicly update or
revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.
Contact:
Avi Minkowitz
Chief Executive Officer,
KALA BIO, Inc.
am@kalarx.com
www.kalarx.com | www.Researgency.ai